This information is intended for US healthcare professionals.
Gilead will send more information about the CD47 pathway and myeloid malignancies directly to your inbox.
Thank you for registering. Gilead will send you more information on the CD47 pathway in cancer.
CD47, cluster of differentiation 47.
Register here, and Gilead will send more information about the CD47 pathway and myeloid malignancies directly to your inbox.
Please fix errors below.
CD47, cluster of differentiation 47; NPI, National Provider Identifier.
Terms & Conditions
Gilead respects the privacy of your personal information. Gilead, and companies providing services to Gilead, may use the information that you provide to send you marketing or informational materials about myeloid malignancies and other updates, analyze and use your information to improve or develop services and programs, and contact you about marketing programs or research and health topics that may be of interest to you.
GILEAD and the GILEAD Logo are trademarks of Gilead Sciences, Inc.
© 2023 Gilead Sciences, Inc. All rights reserved. US-UNBP-2023 08/23